Removal of 2-Arachidonylglycerol by Direct Hemoperfusion Therapy With Polymyxin B Immobilized Fibers Benefits Patients With Septic Shock

被引:22
|
作者
Kase, Yoichi [1 ]
Obata, Toru [2 ]
Okamoto, Yasuhisa
Iwai, Kenichi
Saito, Keita
Yokoyama, Keitaro [3 ]
Takinami, Masanori
Tanifuji, Yasumasa
机构
[1] Jikei Univ, Sch Med, Dept Anesthesiol & Intens Care Med, Minato Ku, Tokyo 1058461, Japan
[2] Jikei Univ, Sch Med, Dept Mol Cell Biol, Tokyo 1058461, Japan
[3] Jikei Univ, Sch Med, Dept Hypertens Med, Inst DNA Med, Tokyo 1058461, Japan
关键词
Arachidonyl ethanolamine; 2-Arachidonylglycerol; Direct hemoperfusion therapy; Endocannabinoid; Polymixin-B; Septic shock;
D O I
10.1111/j.1744-9987.2008.00612.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Arachidonylethanolamide (AEA) and 2-arachidonylglycerol (2-AG) are endocannabinoids involved in septic shock, and 8-epi prostaglandin F2 alpha (F2-isoprostane) is a biomarker of oxidative stress in biological systems. Because the antibiotic polymyxin B absorbs endocannabinoids as well as endotoxins, direct hemoperfusion therapy with polymyxin B-immobilized fibers (PMX-DHP) decreases serum levels of endocannabinoids. To investigate the features of sepsis and determine the proper use of PMX-DHP, we measured the changes in levels of endocannabinoids and F2-isoprostane in patients with septic shock. Twenty-six patients with septic shock, including those with septic shock induced by peritonitis, underwent laparotomy for drainage. Endocannabinoids absorption with PMX-DHP was examined in two groups of patients: patients whose mean arterial blood pressure (mABP) had increased more than 20 mm Hg (responder group; N = 13); and patients iwhose mABP did not increase or had increased no more than 20 mm Hg (non-responder group; N = 13). Levels of AEA did not change after PMX-DHP in either the non-responder or responder groups, whereas levels of 2-AG decreased significantly after PMX-DHP in the responder group, but not in the non-responder group. F2-isoprostane gradually increased after PMX-DHP treatment; on the other hand, levels of F2-isoprostane remained constant in the responder group. Patients with septic shock are under considerable oxidative stress, and 2-AG plays an important role in the cardiovascular status of these patients. The removal of 2-AG by PMX-DHP benefits patients with septic shock by stabilizing cardiovascular status and decreasing long-term oxidative stress.
引用
收藏
页码:374 / 380
页数:7
相关论文
共 50 条
  • [21] Direct hemoperfusion with polymyxin B immobilized fiber (PMX-DHP) for septic shock as categorized by causative pathogens
    Imaizumi, H
    Masuda, Y
    Sato, M
    Ezoe, E
    Takahashi, N
    Yoshida, H
    Khoro, S
    Nishimori, H
    Asai, Y
    None, C
    CRITICAL CARE MEDICINE, 2001, 29 (12) : A89 - A89
  • [22] Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock
    Mitaka, Chieko
    Kusaoi, Makio
    Kawagoe, Izumi
    Satoh, Daizoh
    ACUTE AND CRITICAL CARE, 2021, 36 (02) : 85 - 91
  • [23] Prognostic factors in patients with septic shock in digestive surgery who have undergone direct hemoperfusion with polymyxin B-immobilized fibers: A retrospective observational study
    Matsukuma S.
    Sakamoto K.
    Nishiyama M.
    Tamesa T.
    Yoshino S.
    Hazama S.
    Oshibuchi R.
    Matsuda N.
    Matsumoto S.
    Wakamatsu H.
    Tsuruta R.
    Matsumoto M.
    Oka M.
    Journal of Intensive Care, 3 (1)
  • [24] Polymyxin B-direct hemoperfusion therapy contributes to oxygen delivery in septic patients
    A Yaguchi
    M Yokota
    T Goto
    M Takeda
    R Moroi
    T Harada
    M Namiki
    Critical Care, 16 (Suppl 3):
  • [25] Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock
    Tsujimoto, H
    Ono, S
    Hiraki, S
    Majima, T
    Kawarabayashi, N
    Sugasawa, H
    Kinoshita, M
    Hiraide, H
    Mochizuki, H
    JOURNAL OF ENDOTOXIN RESEARCH, 2004, 10 (04): : 229 - 237
  • [26] Clinical Effects of a Longer Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion Therapy for Severe Sepsis and Septic Shock
    Yamashita, Chizuru
    Hara, Yoshitaka
    Kuriyama, Naohide
    Nakamura, Tomoyuki
    Nishida, Osamu
    THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (04) : 316 - 323
  • [27] Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients
    Lee, Chen-Tse
    Tu, Yu-Kang
    Yeh, Yi-Chun
    Chang, Tzu
    Shih, Po-Yuan
    Chao, Anne
    Huang, Hsing-Hao
    Cheng, Ya-Jung
    Yeh, Yu-Chang
    JOURNAL OF CRITICAL CARE, 2018, 43 : 202 - 206
  • [28] Effect of polymyxin B hemoperfusion on the outcome of patients with sepsis and septic shock
    Lin, Wei-Ting
    Lai, Chih-Cheng
    Wang, Jian-Jhong
    Chao, Chien-Ming
    JOURNAL OF INFECTION, 2020, 80 (03) : 364 - 365
  • [29] The effectiveness of endotoxin removal with polymyxin B immobilized fiber in the septic shock patients.
    Mayumi, T
    Arishima, T
    Takezawa, J
    Fujita, M
    Goto, A
    Sato, T
    Miura, M
    Yamazaki, J
    Furuya, T
    Miyate, Y
    Nagamine, T
    Kodama, A
    Shimazaki, S
    SHOCK, 2005, 23 : 44 - 44
  • [30] Effects of Early Initiation of Polymyxin B Hemoperfusion Therapy in Patients with Cancer with Refractory Septic Shock
    Lee, Jae Hoon
    Han, Won Ho
    Im, Hyun-jae
    Kim, Jee Hee
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)